The efficacy of AN69 membrane for elimination of aminoglycoside.
Not Applicable
Recruiting
- Conditions
- MRSA infection
- Registration Number
- JPRN-UMIN000004486
- Lead Sponsor
- Division of Clinical Pharmacology, Graduate school of Pharmaceutical Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients taking angiotensin-converting enzyme inhibitor. 2) patients having history of hypersensitivity to arbekacin. 3) patients having family with hearing loss. 4) patients being participating other study, and having participated other study within three months. 5) other situation that doctor decides.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change over time of blood concentration of arbekacin.
- Secondary Outcome Measures
Name Time Method Calculation of pharmacokinetic parameters of arbekacin in hemodialysis patients using AN69 dialyzer.